Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

Canadian Cancer Trials Group NEC.2 (CALGB 80701) -- A Randomized Phase II Study of Everolimus Alone versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours -- was closed to accrual October 1, 2012 after meeting its accrual target of 138 patients.

Thanks to all participating Canadian centres, staff and patients for your contributions to making this trial a success.